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tion cost compared to generic risperidone. CONCLUSIONS: Treatment of early 
responders was more cost-effective than the treatment of early non-responders to 
atypical antipsychotic therapy. The treatment of early non-responders who switched 
to olanzapine was more cost-effective than treatment of early non-responders main-
tained on generic risperidone.
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OBJECTIVES: The purpose was to conduct an economic analysis of escitalopram 
(generic drug) versus sertraline and venlafaxine as standard regimen in treatment of 
major depressive disorder (MDD) in Poland. METHODS: Due to lack of statistically 
signiﬁcant differences in comparisons of escitalopram with sertraline and escitalopram 
with venlafaxine, economic proﬁtability estimation was conducted as a cost-minimi-
sation analysis (CMA). Decision model was created by using TreeAge® Pro. Data 
concerning efﬁcacy and safety of compared therapies was based on the clinical-
effectiveness analysis, which was conducted as systematic literature review. Total 
costs of analysed therapies were estimated from the perspective of both payers in 
Poland (National Health Fund and patient) and also from the social perspective. The 
time horizon of the analysis was 6 months. The costs were not discounted. The stabil-
ity of results was checked in one-way and probabilistic sensitivity analyses. Addition-
ally, optimistic and pessimistic scenarios were prepared. RESULTS: Based on the 
assumptions that clinical effects of compared treatment strategies are the same, the 
results of the cost-minimisation analysis are as following: treatment of one patient 
using escitalopram in the 6 month time horizon is 12.71 PLN more expensive then 
sertraline therapy and 135.95 PLN cheaper then therapy with venlafaxine. One-way 
sensitivity analysis conducted for comparison of escitalopram versus sertraline 
showed that results are sensitive on the prices of medicaments. The sensitivity analysis 
conducted for comparison of escitaloprom versus venlafaxine showed the stability of 
basic results. Therapy with escitalopram is cheaper than with venlafaxine for all 
parameters took into account in the sensitivity analysis. CONCLUSIONS: Escitalo-
pram (generic drug) is costly comparable to sertraline and cheaper option of treatment 
in comparison with venlafaxine in the treatment of major depressive disorder in the 
6 month time horizon.
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OBJECTIVES: Opioid addiction is a chronic brain disease with severe withdrawal 
symptoms and decompensated condition in the vicious circle of compulsive drug 
seeking behavior, including needle sharing, psychosocial dysfunction, and criminal 
acts due to ﬁnancial decompensation. Methadone maintenance therapy is the service 
under the concept of harm reduction. We analyzed the estimated utility of prevention 
in the implementation of methadone maintenance therapy introduced in Taiwan since 
2006. METHODS: By using the methadone registry data and the estimation of inci-
dence rates of decompensation with versus without methadone maintenance, the 
expected number of decompensated cases reduced by harm reduction can be calcu-
lated. The utility possibly gained is estimated based on assumption of different values 
of quality of life (QOL) for the decompensation. RESULTS: Based on the imprisoned 
registry of Ministry of Justice and estimations of the Center for Diseases Control, the 
number of heroin addicts in Taiwan was about 100,000, with a total of 15,000 regu-
larly in prison. The yearly number of methadone registry cases reached 15,500 by the 
year-end of 2008. Assuming that annual incidence rates of decompensation were about 
0.1 and 0.7 for heroin addicts with and without methadone therapy, then the annual 
expected number prevented by such treatments would be 9000 with a possible gain 
of utility of 1800 and 4500 QALY (quality-adjusted life year), respectively, depending 
on the reduced utility of 0.2–0.5 for the QOL among decompensated cases. CONCLU-
SIONS: As the annual cost for administration of methadone program was about 
40,000 NTD, which leads to an incremental cost of 66,640 to 166,600 NTD (1 USD 
= 32 NTD) per QALY, without counting the cost of possible harm produced to the 
society by decompensated behaviors. With improved accessibility of methadone main-
tenance therapy, the utility of prevention for the decompensation of heroin addiction 
may be further increased.
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OBJECTIVES: Major depressive disorder (MDD) is a psychiatric condition principally 
characterized by depressive mood, loss of appetite, decreased interest in daily activities, 
sleep, behavioural or attentional disorders, diminution of energy, and feelings of guilt. 
Because MDD is associated with substantial health care costs and productivity losses, 
it wields a considerable economic impact. The aim of this study was to assess, in the 
Canadian context, the economic impact of escitalopram in the treatment of MDD. 
METHODS: A cost-utility analysis was performed over a one-year time horizon from 
societal and health care system perspectives in Canada. A decision tree was developed 
to compare the cost per quality adjusted life year (QALY) associated with the use of 
escitalopram and citalopram. The decision tree, which included patients with MDD 
who had received escitalopram or citalopram as initial treatment, takes into account 
the probability of initial and subsequent treatment remission, of relapse, of suicide 
attempts, and of suicide-related death. Costs included were those of the antidepressant 
drugs, medical visits and hospitalizations, and those associated with remission/non-
remission, relapses, suicide attempts and suicide-related deaths. Costs related to pro-
ductivity loss and societal costs associated with suicide-related deaths were also 
included in the analysis with the societal perspective. Utility values associated with 
remission and non-remission were obtained from the literature. RESULTS: From a 
health care perspective, the incremental cost-utility ratio of escitalopram compared to 
citalopram was estimated at $12,869/QALY. From a societal perspective, escitalopram 
provided more QALYs (+0.0085 QALY/patient) and entailed fewer costs (−$144.70/
patient) compared to citalopram. Deterministic and probabilistic sensitivity analyses 
conﬁrmed the robustness of the base-case results. CONCLUSIONS: The results of 
this economic evaluation indicate that escitalopram is a more cost-effective alternative 
than citalopram to treat MDD from both the health care system and societal 
perspectives.
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OBJECTIVES: The Canadian cost-effectiveness analysis of long-acting risperidone 
versus oral atypical and conventional depot antipsychotics in the treatment of schizo-
phrenia was updated based on results from a study comparing long-acting risperidone 
to depot zuclopenthixol. METHODS: An extensive pharmacoeconomic discrete event 
model was developed to estimate the costs and health beneﬁts of patients treated with 
long-acting risperidone versus oral atypical and conventional depot antipsychotics in 
the treatment of patients with schizophrenia at high-risk of non-compliance over a 
ﬁve-year period. In the original analysis, oral risperidone was considered in the oral 
atypical arm and haloperidol decanoate was considered in the conventional depot arm. 
At the time of the original analysis there were no head-to-head clinical studies which 
compared long-acting risperidone to conventional depots. Since, an open-label, ran-
domized, controlled, assessor-blinded, six-month study comparing long-acting risperi-
done to depot zuclopenthixol has been published. Using these study results, the model 
was updated to consider depot zuclopenthixol as the treatment for the depot compara-
tor arm. The comparator of oral risperidone for the oral atypical arm remained the 
same. RESULTS: The model projected the ﬁve-year cumulative direct costs of 
$155,601, $178,153, and $182,942 (discounted) for long-acting risperidone, oral 
risperidone, and depot zuclopenthixol, respectively. Thus, treatment with long-acting 
risperidone saved approximately $22,552 and $27,341 (discounted) over 5 years 
compared to oral risperidone and depot zuclopenthixol. Moreover, long-acting ris-
peridone resulted in greater decreases in the number of relapses, total time spent in 
psychosis and a greater increase in quality-adjusted-life-years (QALYs) compared to 
oral risperidone or depot zuclopenthixol. Hence, long-acting risperidone is the domi-
nant strategy, being more effective and less costly than oral risperidone or depot 
zuclopenthixol. CONCLUSIONS: Consistent with the original analysis, the current 
analysis demonstrates that long-acting risperidone is a cost-effective option which 
results in better clinical outcomes and lower total health care costs than oral risperi-
done or depot zuclopenthixol.
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OBJECTIVES: This analysis considers the impact of ADHD in adults on 1) labor force 
status, and 2) workplace absenteeism and presenteeism in the US. METHODS: Data 
from the 2009 US National Health and Wellness Survey (NHWS) were used to identify 
all those in the labor force 18 to 49 years of age with a diagnosis of attention deﬁcit 
disorder (ADD) or ADHD. The analysis was in two stages: 1) an evaluation of the 
prevalence of adult ADHD (n = 40,428), and 2) the estimation of logistic regressions 
to assess the contribution of unmedicated/medicated ADHD to labor force status and 
the estimation of ordered probit regressions (n = 25,862) to assess the contribution 
of unmedicated/medicated ADHD to absenteeism and presenteeism. Additional vari-
ables that are considered are socio-demographic status and health risk factors, together 
with the Charlson Comorbidity Index (CCI). RESULTS: An estimated 2.7% had 
diagnosed ADHD. This had a signiﬁcant negative impact on labor force participation 
(odds ratio 0.817), although medicated ADHD had no impact. The presence of 
unmedicated ADHD and medicated ADHD were, however, signiﬁcant at the 1% level 
in both the absenteeism and presenteeism models. Odds ratios in the absenteeism 
model were 4.79 for those with unmedicated ADHD and 3.27 for those with medi-
cated ADHD. These were of a similar magnitude to odds ratios for health risk factors 
(obesity 3.40 and morbid obesity 6.34) but less than the CCI odds ratio 17.43. In the 
presenteeism model, the odds ratios were also signiﬁcant at the 1% level at 8.07 for 
medicated and 6.99 for unmedicated ADHD. CONCLUSIONS: The presence of 
